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ABSTRACT
Liraglutide, a glucagon-like peptide-1 (GLP-1) analog, is increasingly used in obese patients with type 2 diabetes mellitus (T2DM) in doses 
of up to 3.0 mg/day because of its attractive pharmacological profile. It is currently not known how to proceed with this medication during 
fasting for surgery. Discontinuation is likely to result in hyperglycaemia, while continuation might lead to hypoglycaemia, but, in view of its 
mode of action, continuation of GLP-1 analogs is likely to be safe. However, as evidence-based guidelines on GLP-1 management during 
perioperative fasting are not available, the safety of either policy needs to be confirmed on an individual basis. We therefore decided to 
perform a preoperative assessment of the glucose response to fasting during continuation of GLP-1 before giving a recommendation in 
individual cases. So far, 12 severely obese T2DM patients scheduled for bariatric surgery have been evaluated preoperatively by measuring 
glucose and insulin levels during a 32-hour fast with continuation of liraglutide. Hypoglycaemia was not observed. This suggests that 
liraglutide in doses of up to 3.0 mg can be safely continued during surgery without risking hypoglycaemia.
LEARNING POINTS
• Evidence-based guidelines on how to proceed with GLP-1 analogs during perioperative fasting are currently not available.
• Our observations suggest that liraglutide in doses of up to 3.0 mg/day can be safely continued during perioperative fasting for 32 hours.
• Further evaluation is needed for fasting periods longer than 32 hours.
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BACKGROUND 
Liraglutide, a glucagon-like peptide-1 (GLP-1) analog, is increasingly used in obese patients with type 2 diabetes mellitus (T2DM) because of 
its attractive pharmacological profile. It improves glycaemic control, induces weight loss and is associated with a low risk of hypoglycaemia[1]. 
Liraglutide is currently used for the treatment of T2DM in doses of up to 1.8 mg/day and for the treatment of obesity in doses of up to 3.0 
mg/day[2]. As bariatric surgery is a major specialty in our institution, severely obese T2DM patients treated with liraglutide up to 3.0 mg/day 
are frequently referred to the department of internal medicine for advice on how to proceed with this medication during surgery. Should 
it be discontinued and risk hyperglycaemia requiring ad hoc insulin treatment or can it be safely continued and maintain optimal glycaemic 
control? As evidence-based guidelines on GLP-1 treatment during perioperative fasting are not available, we felt that preoperative 
assessment of the glucose response to fasting was warranted before giving perioperative advice in individual cases. 
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This information was obtained by preoperative assessment of the glucose and insulin response during a 32-hour fast while continuing 
liraglutide. The background to this assessment was explained to all patients, and all gave their informed consent prior to testing. 
CASE PRESENTATION
So far, we have evaluated 12 severely obese T2DM patients scheduled for bariatric surgery. They were treated with a combination of 
metformin at a mean±SE daily dose of 2000±296 mg, and liraglutide once or twice daily with a mean±SE daily dose of 2.5±0.2 mg (range: 
1.8–3.0 mg/day). The mean age was 53±2.5 years, body mass index (BMI) was 37.8±2.0 kg/m2, and HbA1c was 54.8±3.2 mmol/mol. 
Measurement of plasma glucose (P800, Roche) and insulin (Immulite XP2000, Siemens) levels every 2–3 hours was started at 12.00 h on 
day 1 while patients continued their usual diet. Fasting for a period of 32 hours was started at 24.00 h on day 1 and continued until 08.00 
h on day 3. Drinking of water was allowed during fasting. On day 3, all patients resumed their usual diet at 08.00 h. The observation period 
ended at 12.00 h. Hypoglycaemia was defined as a plasma glucose level <3.5 mmol/l. 
The results of the preoperative evaluation procedure are shown in Fig. 1. The mean glucose and insulin responses are shown as black dots 
and the individual data as open circles. During the 32-hour fast, mean plasma glucose levels gradually declined from 7.3±0.7 mmol/l to a 
minimum of 5.7±0.3 mmol/l in the first 24 hours and then increased slightly to 6.4±0.6 mmol/l at 32 hours. Insulin levels decreased from 
22.9±3.4 to 8.6±1.8 mU/l and then to 8.3±2.1 mU/l. Nadir glucose levels of individual patients ranged from 4.0 to 6.8 mmol/l. Hypoglycaemia 
was not observed. 
Figure 1. Glucose and insulin responses in patients with type 2 diabetes during fasting. The mean responses are shown as black dots, individual values as open circles. Grey 
area: 32-hour fasting period. Arrows: timing of liraglutide injections
OUTCOME
So far, gastric bypass surgery has been performed in 10 patients. They continued liraglutide at the same dose as used preoperatively, and 
none developed hypoglycaemia. The lowest perioperative glucose level was 5.7 mmol/l, while the highest level was 19.6 mmol/l.
DISCUSSION
These preliminary observations suggest that liraglutide in doses of up to 3.0 mg/day can be safely continued during surgery without risking 
hypoglycaemia. The findings are in agreement with the currently known mode of action of GLP-1 agonists. As the ability of GLP-1 agonists 
to promote insulin secretion depends on the presence of elevated blood glucose levels, their activity ceases when blood glucose levels 
decline[1]. It has been shown that healthy human subjects treated with pharmacological intravenous doses of GLP-1 after an overnight fast 
do not develop hypoglycaemia[2]. GLP-1’s glucose dependence was also nicely demonstrated in euglycaemic clamp studies in fasting healthy 
subjects. Continuous infusion of the GLP-1 agonist exenatide ceased to stimulate insulin secretion when plasma glucose levels dropped to 
4.0 mmol/l or less [3]. 
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A recent study of eight healthy men continuously infused with either a pharmacological dose of native GLP-1 or placebo during a 48-hour 
fast demonstrated that glucose levels declined in a similar manner to a mean of 3.7 mmol/l, with parallel declines in insulin and C-peptide 
levels to a similar extent in both groups[4]. The low risk of hypoglycaemia with high-dose liraglutide was also demonstrated in a study of 93 
non-fasting, non-diabetic obese subjects treated with liraglutide 3.0 mg/day as weight-lowering pharmacotherapy[5]. This observation was 
recently confirmed in a large 56-week placebo-controlled trial evaluating the efficacy and safety of liraglutide 3.0 mg/day in non-diabetic 
obese men and women: spontaneous hypoglycaemia was reported by 32 of 2481 patients (1.3%) in the liraglutide group and by 13 of 1242 
patients (1.0%) in the placebo group[6]. 
To our knowledge, the present report is the first to describe the safety of GLP-1 treatment in fasting T2DM patients. However, the number 
of observations is still too small to generalize these findings. Other limitations are the relatively short fasting period of 32 hours, and the fact 
that only severely obese patients were included. It is not known what will happen if the post-operative fasting period has to be extended 
beyond 32 hours, or what the response will be in normal weight and overweight patients with T2DM. Further evaluation is also needed 
to examine whether the anti-hyperglycemic effects of GLP-1 analogs are sufficiently strong to prevent perioperative, stress-induced 
hyperglycaemia. In view of the increasing use of GLP-1 analogs, we recommend that research is extended so that solid evidence-based 
instructions can be developed. 
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